| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| review article | Q7318358 |
| P50 | author | Sue Bayliss | Q55099983 |
| Jayne Louise Wilson | Q88732958 | ||
| Chris Hyde | Q92346122 | ||
| Andreas Engert | Q99568568 | ||
| Jerome Seidenfeld | Q117273827 | ||
| Josie Sandercock | Q117273828 | ||
| Simon Langensiepen | Q117273829 | ||
| Julia Bohlius | Q28036873 | ||
| Benjamin Djulbegovic | Q28050789 | ||
| Guido Schwarzer | Q28360274 | ||
| Sven Trelle | Q28360282 | ||
| Olaf Weingart | Q28360297 | ||
| P2093 | author name string | Margaret Piper | |
| Charles L Bennett | |||
| P2860 | cites work | Erythropoietin for patients with malignant disease | Q24245427 |
| Erythropoietin, uncertainty principle and cancer related anaemia | Q24791480 | ||
| Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 | ||
| Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer | Q28343446 | ||
| Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis | Q33213775 | ||
| Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials | Q34337012 | ||
| Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy | Q34526421 | ||
| Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study | Q34535702 | ||
| Beneficial and ominous aspects of the pleiotropic action of erythropoietin | Q35868143 | ||
| Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study | Q36222669 | ||
| Impact of epoetin beta on quality of life in patients with malignant disease | Q36646758 | ||
| A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer | Q37340514 | ||
| Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study | Q40373073 | ||
| Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer | Q43877468 | ||
| Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin | Q46104690 | ||
| The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events | Q47445317 | ||
| Erythropoietin regulates tumour growth of human malignancies | Q48280802 | ||
| Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. | Q50976608 | ||
| Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. | Q53326107 | ||
| Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. | Q53326111 | ||
| Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial. | Q53385753 | ||
| Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. | Q53398188 | ||
| Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. | Q53435821 | ||
| Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. | Q53483744 | ||
| Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. | Q53596312 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| erythropoietin | Q218706 | ||
| meta-analysis | Q815382 | ||
| P304 | page(s) | 708-714 | |
| P577 | publication date | 2006-05-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients | |
| P478 | volume | 98 |
| Q51197806 | A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors. |
| Q62223739 | A synthetic approach to 'click' neoglycoprotein analogues of EPO employing one-pot native chemical ligation and CuAAC chemistry |
| Q36246727 | Age-related changes in peripheral blood counts in humans |
| Q40385998 | An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies. |
| Q38545607 | An update on the use of lenalidomide for the treatment of multiple myeloma |
| Q37054981 | Anaemia of cancer: an overview of mechanisms involved in its pathogenesis |
| Q44662005 | Anaemia: a rare but neglected problem among Finnish patients receiving chemotherapy for solid tumours |
| Q44137873 | Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. |
| Q37799923 | Anemia in cancer |
| Q37445907 | Anemia in heart failure: pathophysiologic insights and treatment options |
| Q36716163 | Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols |
| Q37104331 | Anemia of aging: the role of chronic inflammation and cancer |
| Q37281589 | Anemia of critical illness |
| Q33893093 | Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis |
| Q38096441 | Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. |
| Q37006635 | Approaches to risk-stratifying cancer patients for venous thromboembolism. |
| Q37393394 | Assessing risk of venous thromboembolism in the patient with cancer. |
| Q26865716 | Biomolecular markers of cancer-associated thromboembolism |
| Q40070340 | Biosimilars: illustration of scientific issues in two examples |
| Q37416199 | Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer |
| Q57128138 | Can Vulnerable Elders Survey-13 predict the impact of frailty on chemotherapy in elderly patients with gynaecological malignancies? |
| Q36029750 | Canadian supportive care recommendations for the management of anemia in patients with cancer |
| Q38805391 | Cancer associated thrombosis: risk factors and outcomes |
| Q84824465 | Cancer chemotherapy in the older cancer patient |
| Q37393386 | Cancer, clots and consensus: new understanding of an old problem. |
| Q37419795 | Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. |
| Q38086121 | Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. |
| Q80495398 | Cancer-related fatigue: new theories? |
| Q44963037 | Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease |
| Q38399037 | Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes |
| Q50543689 | Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating |
| Q60302337 | Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors |
| Q98183412 | Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis |
| Q26827538 | Clinical problem solving: utility of sonography in oncologic patients |
| Q53196730 | Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly. |
| Q48277049 | Costs of care for lung and colon cancer patients receiving chemotherapy following FDA policy changes |
| Q36974670 | Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals |
| Q33499897 | Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial |
| Q38056750 | Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy |
| Q36657982 | Development and validation of a predictive model for chemotherapy-associated thrombosis |
| Q38188501 | Diagnosis and treatment of cancer-related anemia. |
| Q34446275 | Doping in sport: effects, harm and misconceptions. |
| Q84920116 | Dose reduction of epoetin-alpha in the prevention of chemotherapy-induced anaemia |
| Q53289646 | Downregulation of erythropoietin receptor by overexpression of phospholipase C-gamma 1 is critical for decrease on focal adhesion in transformed cells. |
| Q33387312 | Drug-induced hematologic syndromes |
| Q38103820 | Drug-induced thrombosis: an update |
| Q79408956 | Editorial comment on: "The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced non-small cell lung cancer receiving palliative chemotherapy". by Vincent et al |
| Q34403856 | Effect of erythropoietin levels on mortality in old age: the Leiden 85-plus Study |
| Q36612465 | Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis |
| Q55366199 | Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents. |
| Q30803363 | Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data |
| Q41456026 | Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis |
| Q33726150 | Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial |
| Q48088431 | Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis |
| Q59616802 | Einsatz von Erythropoese-stimulierenden Proteinen bei anämischen Patienten mit malignen Erkrankungen |
| Q35860789 | Epidemiology and pathophysiology of cancer-associated thrombosis |
| Q37242472 | Epidemiology of cancer-related venous thromboembolism |
| Q51049616 | Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy. |
| Q57489994 | Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma |
| Q42765405 | Erythropoiesis-stimulating agents and quality of life: personal journeys of a cancer survivor, oncologist, and two cancer health services researchers |
| Q35642998 | Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes |
| Q24241045 | Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients |
| Q24186244 | Erythropoiesis-stimulating agents for myelodysplastic syndromes |
| Q24202526 | Erythropoiesis-stimulating agents for myelodysplastic syndromes |
| Q39293869 | Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience |
| Q37960528 | Erythropoiesis-stimulating agents in cancer patients: reflections on safety |
| Q33630871 | Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes |
| Q37564558 | Erythropoiesis-stimulating agents in patients with cancer: update on safety issues |
| Q36410646 | Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer |
| Q37098040 | Erythropoietic agents and the elderly |
| Q37693160 | Erythropoietic stimulating agents |
| Q86260187 | Erythropoietin |
| Q48180827 | Erythropoietin Induces an Epithelial to Mesenchymal Transition-Like Process in Mammary Epithelial Cells MCF10A. |
| Q36404124 | Erythropoietin deficiency decreases vascular stability in mice. |
| Q26999850 | Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit |
| Q24245464 | Erythropoietin or Darbepoetin for patients with cancer |
| Q24240202 | Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data |
| Q24242864 | Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data |
| Q24202335 | Erythropoietin or darbepoetin for patients with cancer |
| Q37022662 | Erythropoietin pharmacology. |
| Q38292589 | Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells |
| Q36943310 | Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations |
| Q41969477 | Erythropoietin use in critically ill patients: forest and trees |
| Q30620811 | Exploring the effect of erythropoietin on mortality using USRDS data |
| Q36854821 | Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients |
| Q33659628 | Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer |
| Q35217404 | Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues |
| Q37176449 | G-CSF- and erythropoietin-based cell therapy: a promising strategy for angiomyogenesis in myocardial infarction |
| Q36936723 | Granulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma. |
| Q35174604 | Guidelines for treatment and prevention of venous thromboembolism among patients with cancer |
| Q46246045 | Hematology: ESAs to treat anemia--balancing the risks and benefits |
| Q44420464 | Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes |
| Q36230547 | High expression levels of erythropoietin and its receptor are not correlated with shorter survival in human glioblastoma |
| Q49082528 | High prevalence of anaemia and limited use of therapy in cancer patients: a Belgian survey (Anaemia Day 2008). |
| Q37775781 | Impact of erythropoiesis-stimulating agent prescribing at an Asian cancer center, after release of safety advisories |
| Q37982120 | Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy |
| Q38958980 | In-vivo detection of the erythropoietin receptor in tumours using positron emission tomography |
| Q47262610 | Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. |
| Q58908160 | Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta-analysis |
| Q37661050 | Is there a role for erythropoietin in cardiovascular disease? |
| Q53136003 | Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey. |
| Q37861195 | Management of anemia in cancer patients |
| Q37252771 | Managing anemia in lymphoma and multiple myeloma |
| Q41855598 | Mesenteric infarction due to iatrogenic polycythemia |
| Q60921273 | Methylation of the first exon in the erythropoietin receptor gene does not correlate with its mRNA and protein level in cancer cells |
| Q92774621 | Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies |
| Q92774629 | Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies |
| Q37307380 | New insights into cancer-associated thrombosis |
| Q79642804 | Observational Aranesp Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa |
| Q36801561 | Onco-nephrology: an appraisal of the cancer and chronic kidney disease links |
| Q50621981 | Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand. |
| Q34635638 | Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia |
| Q37117367 | Oxygen delivery enhancers: past, present, and future |
| Q37452747 | Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer |
| Q94526353 | Pharmacological cancer treatment and venous thromboembolism risk |
| Q36890064 | Possible links between behavioral and physiological indices of tiredness, fatigue, and exhaustion in advanced cancer. |
| Q39069010 | Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis |
| Q36875147 | Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. |
| Q38829676 | Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study |
| Q84140441 | Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines |
| Q38115153 | Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review. |
| Q40131701 | Projecting future drug expenditures--2008. |
| Q40006621 | Projecting future drug expenditures--2009. |
| Q84484670 | Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis |
| Q46293619 | Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients |
| Q53226503 | Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. |
| Q35620681 | Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation |
| Q37807314 | Randomized Controlled Trials of the Erythroid-Stimulating Agents in Cancer Patients |
| Q37076291 | Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction |
| Q44710476 | Recognizing the toxicity of "nontoxic" drugs employed in the management of malignant disease |
| Q37230276 | Recombinant human epoetin beta in the treatment of chemotherapy-related anemia |
| Q44730385 | Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials |
| Q48640784 | Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients |
| Q36963831 | Recommendation of the scientific societies on the treatment of anaemia in cancer patients |
| Q39749243 | Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions |
| Q35164312 | Risks of Venous Thromboembolism and Mortality Associated With Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Associated Anemia. |
| Q37071262 | Role of erythropoietin in cancer-related anaemia: a double-edged sword? |
| Q84080832 | Role of erythropoietin receptor expression in malignant melanoma |
| Q36689075 | Safety considerations for erythropoietin treatment in patients with cancer |
| Q33985838 | Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes |
| Q36851424 | Senior adult oncology |
| Q38092791 | Should We Use Preoperative Epoetin-α in the Mildly Anemic Patient Undergoing Simultaneous Total Knee Arthroplasty? |
| Q50592725 | Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. |
| Q36728021 | Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins |
| Q37702827 | Supportive care in hemato-oncology: a review in light of the latest guidelines |
| Q30444752 | Supportive management of patients with brain tumors |
| Q38786007 | Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. |
| Q34022950 | The ESA APPRISE Oncology Program: A History of REMS Requirements, a Review of the Data, And an Approach to Compliance in the Hospital |
| Q50613206 | The Polish Cancer Anemia Survey (POLCAS): a retrospective multicenter study of 999 cases. |
| Q38740871 | The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease |
| Q36091004 | The Use of Epoetin-α in Revision Knee Arthroplasty |
| Q38013113 | The Use of Preoperative Epoetin-α in Revision Hip Arthroplasty |
| Q37260416 | The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model |
| Q36291259 | The evolving role of biosimilars in haematology-oncology: a practical perspective |
| Q37433907 | The relationship between anemia and recurrence of ischemic stroke in patients with Trousseau's syndrome: A retrospective cross-sectional study. |
| Q57422687 | The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure |
| Q86828235 | Therapeutic options to minimize allogeneic blood transfusions and their adverse effects in cardiac surgery: a systematic review |
| Q33392897 | Thromboembolic and bleeding complications in acute leukemia |
| Q37863640 | Thrombophilic state in cancer, part I: biology, incidence, and risk factors |
| Q41838949 | Thrombopoietin Protects the Brain and Improves Sensorimotor Functions: Reduction of Stroke-Induced MMP-9 Upregulation and Blood—Brain Barrier Injury |
| Q37023306 | Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer |
| Q33437325 | Thrombosis in the setting of cancer. |
| Q37854580 | Today's challenges in pharmacovigilance: what can we learn from epoetins? |
| Q45256331 | Transfusion alert for patients with curable cancer |
| Q82493209 | Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial |
| Q37352471 | Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). |
| Q45330459 | Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008. |
| Q37328830 | Tumor progression associated with erythropoiesis-stimulating agents |
| Q50547672 | Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. |
| Q79865470 | VEGF inhibitors make blood |
| Q60960811 | Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with Early Onset |
| Q26741697 | Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants |
| Q38944457 | Venous Thromboembolism in Patients Diagnosed With Lung Cancer |
| Q37416512 | Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors |
| Q37688960 | Venous thromboembolism and cancer: a systematic review |
| Q33419213 | Venous thromboembolism in cancer patients |
| Q37051664 | Venous thromboembolism in cervical cancer |
| Q26996508 | Venous thromboembolism in the cancer population: pathology, risk, and prevention |
| Q37190522 | Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis |
| Q38130141 | Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis |
| Q27009514 | What is the Best Treatment for a Cancer Patient with Thrombosis? |
| Q54434317 | [Iron deficiency, thrombocytosis and thromboembolism]. |
Search more.